Lexeo Therapeutics, Inc. Common Stock

LXEONASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
4.69 USD
↗ 0.13 (2.85%)AT CLOSE (11:59 AM EDT)
4.58
↘ 0.11 (2.32%)
POST MARKET (AS OF 07:25 PM EDT)
Post Market
AS OF 07:25 PM EDT
4.58
↘ 0.11 (2.32%)
🔴Market: CLOSED

Lexeo Therapeutics, Inc. Common Stock (LXEO) trades at $4.68 per share. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest LXEO is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jul 17, 2026.

Open?$4.47
High?$4.75
Low?$4.47
Prev. Close?$4.56
Volume?730.1K
Avg. Volume?924.4K
VWAP?$4.66
Rel. Volume?0.79x
Bid / Ask
Bid?$4.05 × 100
Ask?$5.94 × 100
Spread?$1.89
Midpoint?$5.00
Valuation & Ratios
Market Cap?358.1M
Shares Out?78.5M
Float?76.6M
Float %?97.6%
P/E Ratio?N/A
P/B Ratio?1.55
EPS?-$1.11
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
59
Market Cap
358.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.lexeotx.com
Listed
2023-11-03
Address
345 PARK AVENUE SOUTH
NEW YORK, NY 10010
Phone: (212) 547-9879
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
77
Short Sent.?
14
Piotroski F-Score?0/9Weak
Altman Z-Score?8.76Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?21.04%Squeeze Risk
Short Interest?16.1M
Days to Cover?14.0
Free Float76.6M
Avg Daily Volume1.2M
Settlement Date2026-06-30
Financial Health
Current Ratio?14.16Strong
Quick Ratio?14.16Strong
Cash Ratio?5.06Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
86
1.55CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.9CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-37.8%WEAK▾
ROA?
S&P
3
-34.9%WEAK▾
Cash Flow & Enterprise
FCF?$-98421000
Enterprise Value?$287.0M
Fundamentals ratios updated end of day
MarketsMoversWatchlist